76,728 Shares in RxSight, Inc. $RXST Bought by Dynamic Technology Lab Private Ltd

Dynamic Technology Lab Private Ltd bought a new position in RxSight, Inc. (NASDAQ:RXST) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 76,728 shares of the company’s stock, valued at approximately $997,000. Dynamic Technology Lab Private Ltd owned about 0.19% of RxSight at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. State of Wyoming boosted its holdings in shares of RxSight by 91.5% in the first quarter. State of Wyoming now owns 2,062 shares of the company’s stock valued at $52,000 after purchasing an additional 985 shares during the period. Bessemer Group Inc. acquired a new stake in shares of RxSight in the 2nd quarter worth $33,000. Russell Investments Group Ltd. raised its stake in RxSight by 161.2% in the first quarter. Russell Investments Group Ltd. now owns 4,091 shares of the company’s stock valued at $103,000 after buying an additional 2,525 shares during the last quarter. CWM LLC raised its position in shares of RxSight by 614.1% in the 2nd quarter. CWM LLC now owns 4,520 shares of the company’s stock valued at $59,000 after purchasing an additional 3,887 shares during the last quarter. Finally, AlphaQuest LLC raised its holdings in shares of RxSight by 66.0% in the first quarter. AlphaQuest LLC now owns 8,443 shares of the company’s stock worth $213,000 after buying an additional 3,357 shares during the last quarter. Institutional investors own 78.78% of the company’s stock.

RxSight Trading Up 13.4%

Shares of NASDAQ:RXST opened at $10.15 on Friday. The company has a market capitalization of $417.37 million, a price-to-earnings ratio of -11.53 and a beta of 1.16. RxSight, Inc. has a 12-month low of $6.32 and a 12-month high of $47.89. The business has a 50-day moving average price of $8.91 and a 200 day moving average price of $10.42.

RxSight (NASDAQ:RXST) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.15. RxSight had a negative net margin of 25.15% and a negative return on equity of 12.82%. The business had revenue of $30.34 million for the quarter, compared to the consensus estimate of $25.63 million. During the same period in the previous year, the firm earned ($0.16) EPS. The business’s revenue was down 31.4% on a year-over-year basis. RxSight has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that RxSight, Inc. will post -0.7 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on RXST. Wells Fargo & Company lifted their price objective on shares of RxSight from $9.00 to $10.00 and gave the company an “equal weight” rating in a research note on Thursday, November 6th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of RxSight in a research note on Wednesday, October 8th. UBS Group cut their price target on shares of RxSight from $16.00 to $8.00 and set a “neutral” rating for the company in a report on Friday, August 8th. JPMorgan Chase & Co. upped their price target on shares of RxSight from $8.00 to $9.00 and gave the stock an “underweight” rating in a research report on Thursday, November 6th. Finally, Stifel Nicolaus set a $10.00 price target on RxSight in a research note on Thursday, November 6th. One investment analyst has rated the stock with a Buy rating, nine have issued a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, RxSight currently has a consensus rating of “Reduce” and an average price target of $9.56.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.